-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
-
Summary
-
BriaCell Therapeutics Corp. quarterly/annual General and Administrative Expense history and growth rate from Q3 2021 to Q2 2024.
- BriaCell Therapeutics Corp. General and Administrative Expense for the quarter ending July 31, 2024 was $1.36M, a 46.3% decline year-over-year.
- BriaCell Therapeutics Corp. General and Administrative Expense for the twelve months ending July 31, 2024 was $6.15M, a 22.5% decline year-over-year.
- BriaCell Therapeutics Corp. annual General and Administrative Expense for 2024 was $6.15M, a 22.5% decline from 2023.
- BriaCell Therapeutics Corp. annual General and Administrative Expense for 2023 was $7.94M, a 9.19% increase from 2022.
- BriaCell Therapeutics Corp. annual General and Administrative Expense for 2022 was $7.27M, a 46.7% increase from 2021.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Growth (%)